Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors

Area of Science:

• Epigenetics
• Medicinal Chemistry
• Computational Biology

Background:

• Epigenetic modifications regulate gene expression and are crucial in cancer development.
• DNA methyltransferase (DNMT) and histone deacetylase (HDAC) enzymes are key epigenetic regulators implicated in various cancers.
• Targeting DNMT and HDAC enzymes offers a promising strategy for cancer chemotherapy.

Purpose of the Study:

• To introduce novel dual small molecule inhibitors targeting both histone deacetylase 8 (HDAC8) and DNA methyltransferase 1 (DNMT1).
• To explore these dual inhibitors as potential epigenetic-based cancer therapeutics.
• To evaluate the binding interactions and conformational stability of the designed inhibitors.

Main Methods:

• Pharmacophore-based virtual screening of ZINC and Maybridge databases.
• Molecular docking and molecular dynamics simulations.
• Free binding energy calculations and experimental validation.

Main Results:

• Identified novel dual inhibitors with favorable conformations for HDAC8 and DNMT1.
• Demonstrated strong binding interactions between the designed compounds and the HDAC8 enzyme.
• Experimental assays confirmed the virtual screening predictions for inhibitor efficacy.

Conclusions:

• The developed dual inhibitors represent promising candidates for epigenetic cancer therapy.
• These findings provide a foundation for further optimization of inhibitors for enhanced anti-cancer efficacy.
• This study highlights the potential of targeting both DNMT1 and HDAC8 simultaneously for novel cancer treatments.